Introduction
Methods
Study population and settings
Primary outcome
Secondary outcome
Data collections and definitions
Sample size and statistical analysis
Results
Characteristics | All patients, N = 739 | Hydroxocobalamin, N = 386 | No hydroxocobalamin, N = 353 | p |
---|---|---|---|---|
At admission | ||||
- Age in years | 50 (36–63) | 50 (38–62) | 48 (33–64) | 0.4858 |
- Sex female, n (%) | 271 (36.7) | 140 (36.3) | 131 (37.1) | 0.9335 |
- BMI in kg/m2 | 25 (22–28) | 24 (22–28) | 25 (22–28) | 0.2416 |
- Prehospital cardiac arrest (%) | 46 (6.2) | 42 (10.9) | 4 (1.1) | < 0.0001 |
- Prehospital GSC /15 | 15 (9–15) | 13 (5–15) | 15 (14–15) | < 0.0001 |
Comorbidities | ||||
- CKD, n (%) | 6 (0.8) | 6 (1.6) | 0 (0) | 0.0315 |
- CHT, n (%) | 141 (19.1) | 71 (18.4) | 70 (19.9) | 0.6872 |
- Diabetes mellitus, n (%) | 54 (7.3) | 33 (8.5) | 21 (6) | 0.2243 |
- Peripheral artery disease, n (%) | 22 (3) | 9 (2.3) | 13 (3.7) | 0.3882 |
- CHF, n (%) | 33 (4.5) | 20 (5.2) | 13 (3.7) | 0.4197 |
Burn characteristic | ||||
- Burn, n (%) | 577 (78.1) | 286 (74.1) | 291 (82.4) | 0.0081 |
- TBSA % | 20 (3–47) | 15 (0–45) | 24 (6–50) | 0.0163 |
- Deep burn TBSA % | 9 (0–30) | 5 (0–30) | 10 (0–32) | 0.1985 |
SOFA at admission | 4 (1–7) | 5 (2–8) | 2 (0–5) | < 0.0001 |
MAP in mmHg | 86 (72–101) | 86 (68–101) | 86 (73–101) | 0.4383 |
Vasopressors, n (%) | 226 (30.6) | 153 (39.6) | 73 (20.7) | < 0.0001 |
HbCO % | 3.6 (1.9–9.7) | 7 (3–15) | 3 (2–5) | < 0.0001 |
Biological data | ||||
- Plasma lactate in mmol/L | 3.0 (1.8–5.2) | 3.5 (2.1–6) | 2.6 (1.4–4.1) | < 0.0001 |
- Serum creatinine at admission in μmol/L | 76 (59–101) | 82 (63–106) | 71 (56–93) | 0.0031 |
- Maximal serum creatinine in μmol/L | 100 (73–162) | 108 (77–182) | 90 (71–137) | 0.0027 |
Inhalation fibroscopic status, n (%) | 305 (41.3) | 105 (27.5) | 200 (56.7) | < 0.0001 |
- Grade 0, n | 1 (0.1) | 0 (0) | 1 (0.3) | 1 |
- Grade 1, n | 121 (16.4) | 31 (8) | 90 (25.5) | < 0.0001 |
- Grade 2, n | 110 (14.9) | 37 (9.6) | 73 (20.7) | < 0.0001 |
- Grade 3, n | 73 (9.9) | 37 (9.6) | 36 (10.2) | 0.8764 |
During ICU hospitalization | ||||
- In-ICU mortality, n (%) | 243 (32.9) | 147 (38.1) | 96 (27.2) | 0.0022 |
- AKI in the first week, n (%) | 288 (39) | 166 (43) | 122 (34.6) | 0.0229 |
- Stage of AKI | ||||
- Stage 1, n (%) | 102 (13.8) | 52 (13.5) | 50 (14.2) | 0.8682 |
- Stage 2, n (%) | 39 (5.3) | 22 (5.7) | 17 (4.8) | 0.7099 |
- Stage 3, n (%) | 147 (19.9) | 92 (23.8) | 55 (15.6) | 0.0066 |
- Severe AKI, n (%) | 186 (25.2) | 114 (29.5) | 72 (20.4) | 0.0055 |
RRT at day 7, n (%) | 136 (18.8) | 86 (22.3) | 50 (14.2) | 0.006 |
- RRT in ICU, n (%) | 183 (24.8) | 107 (27.7) | 76 (21.5) | 0.0626 |
- MAKE, n (%) | 313 (42.4) | 187 (48.4) | 126 (35.7) | 0.0006 |
- Shock in ICU, n (%) | 402 (54.4) | 225 (58.3) | 176 (50) | 0.0261 |
- Length of stay in ICU in days | 15 (3–44) | 11 (2–36) | 22 (3–50) | 0.0161 |
- SAPS2 | 42 (27–60) | 49 (31–77) | 37 (23–54) | < 0.0001 |
- In-ICU survival, n (%) | 496 (67.1) | 239 (61.9) | 257 (72.8) | 0.0022 |
Nephrotoxic in ICU | ||||
- Aminoglycoside during hospitalization | 188 (25.4) | 81 (21) | 107 (30.3) | 0.0047 |
- Glycopeptide during hospitalization | 41 (5.5) | 16 (4.1) | 25 (7.1) | 0.1138 |
- Contrast agent | 74 (10) | 48 (12.4) | 26 (7.4) | 0.0299 |
Acute kidney injury
Variable | Adjusted odds ratio | LCI | UCI | p |
---|---|---|---|---|
AKI | ||||
Hydroxocobalamin | 1.597 | 1.055 | 2.419 | 0.027 |
Severe burn | 2.91 | 1.841 | 4.601 | < 0.001 |
SOFA score without renal item | 1.003 | 0.891 | 1.129 | 0.963 |
Prehospital GCS | 1.064 | 0.997 | 1.136 | 0.063 |
Aminoglycoside during hospitalization | 2.903 | 1.184 | 4.473 | < 0.001 |
Glycopeptide during hospitalization | 1.731 | 0.773 | 3.877 | 0.182 |
Admission plasma lactate | 1.105 | 1.034 | 1.182 | 0.003 |
Age | 1.009 | 0.997 | 1.021 | 0.154 |
Peripheral arterial obstructive disease | 0.913 | 0.308 | 2.713 | 0.87 |
Diabetes mellitus | 1.487 | 0.726 | 3.046 | 0.278 |
Chronic hypertension | 2.134 | 1.248 | 3.649 | 0.006 |
CKD | 0.947 | 0.119 | 7.504 | 0.959 |
Prehospital cardiac arrest | 0.418 | 0.025 | 7.096 | 0.546 |
Vasopressor at admission | 1.778 | 0.93 | 3.396 | 0.081 |
Maximum CPK | 1.081 | 0.997 | 1.242 | 0.269 |
Contrast agent | 1.445 | 0.803 | 2.601 | 0.219 |
SAPS2 | 1.021 | 1.006 | 1.036 | 0.009 |
Center | 1.014 | 0.976 | 1.053 | 0.484 |
Interaction between prehospital cardiac arrest and hydroxocobalamin | 2.245 | 0.125 | 40.367 | 0.583 |
Severe AKI | ||||
Hydroxocobalamin | 1.772 | 1.137 | 2.762 | 0.012 |
Age | 1.006 | 0.993 | 1.019 | 0.394 |
Peripheral arterial obstructive disease | 0.552 | 0.183 | 1.668 | 0.292 |
Diabetes mellitus | 1.201 | 0.582 | 2.479 | 0.619 |
Chronic hypertension | 2.045 | 1.168 | 3.579 | 0.012 |
Prehospital cardiac arrest | 0.775 | 0.043 | 14.12 | 0.863 |
Severe burn | 2.157 | 1.276 | 3.645 | 0.004 |
SOFA score at admission without renal item | 1.047 | 0.924 | 1.185 | 0.471 |
CKD | 2.407 | 0.285 | 20.299 | 0.418 |
Vasopressor at admission | 1.298 | 0.653 | 2.579 | 0.456 |
Prehospital GCS | 1.04 | 0.973 | 1.11 | 0.248 |
Admission plasma lactate | 1.151 | 1.062 | 1.248 | 0.001 |
Maximum CPK | 1.099 | 0.904 | 1.337 | 0.324 |
Aminoglycoside during hospitalization | 2.418 | 1.539 | 3.801 | < 0.001 |
Contrast agent | 0.889 | 0.476 | 1.663 | 0.713 |
Glycopeptide during hospitalization | 2.873 | 1.318 | 6.261 | 0.008 |
SAPS2 | 1.02 | 1.006 | 1.035 | 0.006 |
Center | 1.042 | 0.998 | 1.089 | 0.061 |
Interaction between prehospital cardiac arrest and hydroxocobalamin | 0.412 | 0.02 | 8.331 | 0.563 |
ICU mortality
Characteristics | All patients, N = 739 | Survivors, N = 496 | Non-survivors, N = 243 | p |
---|---|---|---|---|
At admission | ||||
- Age in years | 50 (36–63) | 46 (33–59) | 56 (43–72) | < 0.0001 |
- Sex female, n (%) | 271 (36.7) | 180 (36.3) | 91 (37.4) | 0.8214 |
- BMI in kg/m2 | 25 (22–28) | 24 (22–28) | 25 (22–29) | 0.0822 |
- Prehospital cardiac arrest (%) | 46 (6.2) | 11 (2.2) | 35 (14.4) | < 0.0001 |
- Prehospital GSC /15 | 15 (9–15) | 15 (13–15) | 14 (3–15) | < 0.0001 |
Comorbidities | ||||
- CKD, n (%) | 6 (0.8) | 2 (0.4) | 4 (1.6) | 0.0948 |
- Hypertension, n (%) | 141 (19.1) | 81 (16.3) | 60 (24.7) | 0.0088 |
- Diabetes mellitus, n (%) | 54 (7.3) | 28 (5.6) | 26 (10.7) | 0.0198 |
- CAOD, n (%) | 22 (3) | 7 (1.4) | 15 (6.2) | 0.0008 |
- CHF, n (%) | 33 (4.5) | 20 (4) | 13 (5.3) | 0.4858 |
Burn characteristic | ||||
- Burn, n (%) | 577 (78.1) | 357 (72) | 220 (90.5) | < 0.0001 |
- TBSA % | 20 (3–47) | 12 (0–30) | 50 (20–73) | < 0.0001 |
- 3rd degree TBSA % | 9 (0–30) | 2 (0–15) | 33 (10–58) | < 0.0001 |
SOFA at admission | 4 (1–7) | 2 (1–5) | 7 (3–10) | < 0.0001 |
MAP in mmHg | 86 (72–101) | 89 (76–102) | 80 (62–97) | < 0.0001 |
Vasopressor, n (%) | 226 (30.6) | 90 (18.1) | 136 (56) | < 0.0001 |
Hydroxocobalamin, n (%) | 386 (52.2) | 239 (48.2) | 147 (60.5) | 0.0021 |
HbCO % | 4 (2–10) | 4 (2–11) | 3 (2–7) | 0.0323 |
Biological data | ||||
- Plasmatic lactate in mmol/L | 3.0 (1.8–5.2) | 2.5 (1.4–3.8) | 4.8 (3–7.6) | < 0.0001 |
- Serum creatinine in μmol/L | 76 (59–101) | 71 (56–88) | 100 (72–123) | < 0.0001 |
- Maximal serum creatinine in μmol/L | 100 (73–162) | 84 (68–113) | 137 (102–212) | < 0.0001 |
Inhalation fibroscopic status (%) | 305 (41.3) | 175 (35.3) | 130 (53.5) | < 0.0001 |
- Grade 0, n | 1 (0.1) | 1 (0.2) | 0 (0) | 1 |
- Grade 1, n | 121 (16.4) | 90 (18.2) | 31 (12.8) | 0.0795 |
- Grade 2, n | 110 (14.9) | 67 (13.5) | 43 (17.7) | 0.1638 |
- Grade 3, n | 73 (9.9) | 17 (3.4) | 56 (23.1) | < 0.0001 |
- During ICU hospitalization | ||||
- AKI in the first week, n (%) | 288 (39) | 126 (25.4) | 162 (66.7) | < 0.0001 |
- Stage of AKI day 7 | ||||
- Stage 1, n (%) | 102 (13.8) | 63 (12.7) | 39 (16) | 0.2601 |
- Stage 2, n (%) | 39 (5.3) | 16 (3.2) | 23 (9.5) | 0.0007 |
- Stage 3, n (%) | 147 (19.9) | 47 (9.5) | 100 (41.2) | < 0.0001 |
- Severe AKI | 186 (25.2) | 63 (12.7) | 123 (50.6) | < 0.0001 |
- RRT at day 7, n (%) | 136 (18.8) | 44 (8.9) | 92 (37.9) | < 0.0001 |
- RRT in ICU, n (%) | 183 (24.8) | 58 (11.7) | 125 (51.4) | < 0.0001 |
- MAKE, n (%) | 313 (42.4) | 69 (13.9) | 243 (100) | < 0.0001 |
- Shock in ICU, n (%) | 402 (54.4) | 191 (38.5) | 211 (86.8) | < 0.0001 |
- Length of stay in ICU | 15 (3–44) | 25 (4–50) | 6 (1–24) | 0.0001 |
- SAPS2 | 42 (27–60) | 32 (22–46) | 61 (46–75) | < 0.0001 |
Nephrotoxic in ICU | ||||
- Aminoglycoside | 188 (25.4) | 115 (23.2) | 73 (42.9) | 0.0548 |
- Vancomycin | 41 (5.5) | 22 (4.4) | 19 (7.8) | 0.4011 |
- Contrast product | 74 (10) | 41 (8.3) | 33 (13.6) | 0.0331 |
ICU mortality | ||||
---|---|---|---|---|
Variable | Adjusted odds ratio | LCI | UCI | p |
Hydroxocobalamin | 1.114 | 0.691 | 1.797 | 0.657 |
Age | 1.037 | 1.023 | 1.05 | < 0.001 |
Prehospital cardiac arrest | 1.091 | 0.07 | 17.126 | 0.95 |
Severe burn | 4.792 | 2.665 | 8.617 | < 0.001 |
SOFA score at admission | 1.074 | 0.942 | 1.225 | 0.283 |
Admission plasma lactate | 1.256 | 1.154 | 1.366 | < 0.001 |
Vasopressors at admission | 1.571 | 0.737 | 3.346 | 0.241 |
Prehospital GCS | 1.033 | 0.961 | 1.11 | 0.383 |
SAPS2 | 1.039 | 1.02 | 1.059 | < 0.001 |
Center | 1.084 | 1.033 | 1.137 | 0.001 |
Interaction between prehospital cardiac arrest and hydroxocobalamin | 6.327 | 0.354 | 112.993 | 0.209 |